CN103933216B - A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application - Google Patents
A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application Download PDFInfo
- Publication number
- CN103933216B CN103933216B CN201410083094.3A CN201410083094A CN103933216B CN 103933216 B CN103933216 B CN 103933216B CN 201410083094 A CN201410083094 A CN 201410083094A CN 103933216 B CN103933216 B CN 103933216B
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- root
- capsule
- mixture
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application, it is a kind of preparation technology for treating the compound blood pressure reducing capsule of the various metabolic disorders of metabolic hypertension, which adopts the raw material red sage root, cassia seed, the root bark of Chinese wolf-berry, the root of bidentate achyranthes, the bark of eucommia and parasitic loranthus, through carrying out alcohol extracting to the red sage root, cassia seed, the root bark of Chinese wolf-berry and the root of bidentate achyranthes, the dregs of a decoction produced after alcohol extracting add the bark of eucommia and parasitic loranthus and carry out mixing water extraction, alcohol extract and Aqueous extracts concentrate drying are made into particle, is loaded capsule and is made product Chinese patent drug.Designed for the various metabolic disorders of metabolic hypertension by the compound blood pressure reducing capsule that the preparation technology of the present invention makes, it is intended to while stabilizing blood pressure, reach the function of adjusting blood pressure and blood lipoid metabolism, the control that metabolism is conducive to blood pressure again is adjusted simultaneously, treat both principal and secondary aspect of disease, it is significant for the preventing and treating of metabolic high blood pressure.
Description
Technical field
The present invention relates to a kind of Chinese patent drug and its preparation and application, more particularly to a kind of treat answering for metabolic high blood pressure
Square blood pressure decreasing capsule and its preparation and application.
Background technology
The concept of metabolic hypertension was proposed that he points out the high blood for merging metabolic disorder first by Poolare in 1993
Pressure patient only relies on simple step-down and does not consider that whole metabolic disorder can not necessarily substantially reduce the incidence of coronary heart disease.It is domestic to learn
Person further explains, and metabolic hypertension is that a kind of and metabolic disorder has clear and definite causality, eliminates endocrine system disease, kidney again
The secondary hypertensions such as popular name for change, aorto-arteritis, contribute to the hypertension of controlling of blood pressure again by improving metabolic risk factors.And
Metabolic hypertension is pointed out for metabolic disorder formerly, blood pressure is raised rear, and hypertensive patients metabolism is after to be often blood pressure raise
There is metabolic disorder, its main distinction is that causality is different.
Anomalous lipid metablism, diabetes and obesity are to cause the basic reason of metabolic hypertension, target organ damage.Due to generation
Thank abnormal first, body and many target organs before blood pressure is raised occur and just had resulted in different degrees of damage, prior to blood
The harm that pressure raises the various metabolic disorders for occurring is even more serious, it should draw attention.Western medicine of depressurization is unable to effective control metabolism
Disorder, is unfavorable for the target organ damage for protecting metabolic disorder to cause.If while be depressured using multi-medicament, lipid-loweringing, hypoglycemic,
Medication is inconvenient, and financial cost is also higher.
The traditional Chinese medical science is fully recognized that the Etiological and characteristics of incidence of metabolic hypertension from entirety, the spleen-warm syndrome it is theoretical from
The aspects such as the cause of disease, symptom, mechanism, treatment are preferably explained to metabolic hypertension；Chinese medicine has multi-target effect, takes into account
Step-down and Metabolism regulation, when metabolic high blood pressure is treated with distinct characteristic and advantage.
The content of the invention
The technical problem to be solved in the present invention is to overcome the deficiencies in the prior art, there is provided a kind of for the high blood for the treatment of metabolic
The compound blood pressure reducing capsule of the various metabolic disorders of pressure and its preparation and application.
To solve above-mentioned technical problem, technical scheme proposed by the present invention is：
A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure, it is characterised in that the compound blood pressure reducing capsule is filled out
If fill owner by made by Traditional Chinese drug mixture A alcohol extracting concentrate and water extracting liquid ECDC made by Traditional Chinese drug mixture B simultaneously, it is dry
The extract powder composition obtained after dry, crushing；
The Traditional Chinese drug mixture A includes：5 ~ 10 mass parts of the red sage root, 10 ~ 15 mass parts of the root of bidentate achyranthes, 10 ~ 30 mass parts of the root bark of Chinese wolf-berry
With 5 ~ 10 mass parts of cassia seed；
The Traditional Chinese drug mixture B includes：10 ~ 15 mass parts of the bark of eucommia, 10 ~ 15 mass parts of parasitic loranthus and Traditional Chinese drug mixture A systems
The dregs of a decoction that standby alcohol extract is produced；
Quality of the filler of the compound blood pressure reducing capsule also including green-tea extract, the extract powder and green-tea extract
Than for (2 ~ 5):1.
Above-mentioned compound blood pressure reducing capsule, its preparation method is from the raw material constituent for including following mass fraction proportioning：
1 ~ 5 part of green-tea extract
5 ~ 10 parts of the red sage root
10 ~ 15 parts of the root of bidentate achyranthes
10 ~ 30 parts of the root bark of Chinese wolf-berry
10 ~ 15 parts of the bark of eucommia
5 ~ 10 parts of cassia seed
10 ~ 15 parts of parasitic loranthus
Based on above-mentioned raw materials, the preparation method is comprised the following steps：
（1）Alcohol extracting：The above-mentioned red sage root, cassia seed, the root bark of Chinese wolf-berry and the root of bidentate achyranthes are weighed according to above-mentioned mass fraction proportioning and are mixed,
Mixture A is obtained, with ethanol solution refluxing extraction at least twice, last alcohol extract passes through decompression or is concentrated in vacuo to without alcohol taste,
Alcohol extracting concentrate is obtained, it is standby；
（2）Water extraction：To step（1）Add the bark of eucommia and parasitic loranthus of above-mentioned mass parts in the dregs of a decoction after middle alcohol extracting, must mix
Thing B, to mixture B water extractions at least twice, last Aqueous extracts obtain water extraction concentration by reducing pressure or being concentrated in vacuo to thick medicinal extract
Liquid, it is standby；
（3）Powder processed：By step（1）The alcohol extracting concentrate for obtaining and step（2）After the water extracting liquid for obtaining merges mixing
Be vacuum dried, obtained dry extract, dry extract is crushed, cross 20 ~ 100 mesh sieves, obtain extract powder, by extract powder weight add 5 ~
30% green-tea extract powder, is well mixed, as capsule filling；
（4）Make finished product：By step（3）The capsule filling for obtaining loads capsule, and packaging obtains compound blood pressure reducing capsule
Finished product.
In step（1）In, it is that the addition of ethanol solution is respectively twice in front and back twice with the number of times that alcohol reflux is extracted
5 ~ 15 times and 3 ~ 10 times of mixture A gross masses, the respectively 0.5 ~ 2h and 0.5 ~ 1h of reflux extracting time twice, described in front and back
The concentration of ethanol solution is 50 ~ 90%；Temperature concentrated in vacuo is 50 ~ 70 DEG C, and vacuum is -0.1Mpa.
In step（2）In, it is that twice, the amount of water of water extraction twice respectively mixes in front and back to the water extraction number of times of mixture B
5 ~ 10 times and 3 ~ 8 times of thing B gross masses, by the advance 0.5 ~ 1h of immersion of mixture B before first time water extraction is carried out, water twice in front and back
The time for carrying is respectively 0.5 ~ 3h and 0.5 ~ 2h；Temperature concentrated in vacuo be 60 ~ 80 DEG C, vacuum be -0.1Mpa, the thick leaching of gained
The density of cream is 1.10 ~ 1.15.
In step（3）In, vacuum drying temperature is 50 ~ 70 DEG C, and vacuum is -0.1Mpa, 12 ~ 24h of drying time.
In the present invention, preparing for treating answering in metabolic hypertension disease medicament including the compound blood pressure reducing capsule
With.
In the present invention, in raw material, the pharmacology of each component is：
The red sage root：For the dry root and rhizome of labiate red sage root Salvia miltiorrhiza Bge..With promoting blood circulation
The effects such as dissolving stasis, inducing meastruation to relieve menalgia, relieving restlessness that clears away heart-fire, cool blood to disappear carbuncle.Modern pharmacological research shows that the red sage root has anti-platelet aggregation, drop
Blood coagulation system inside and outside low blood viscosity and regulation, antiatherosclerosis, chronic hepatitis protection, the protection of lung fiber, anti-inflammatory etc. are made
With.Its main chemical compositions is fat-soluble and water miscible, each with different pharmacological actions.It is fat-soluble including various phenanthrene
Quinone derivative, such as salvia miltiorrhiza bge I, Tanshinone II, Cryptotanshinone, dihydrotanshinone, Isotanshinone Ⅰ, IsotanshinoneⅡ, the different hidden red sage root
Ketone, miltionone etc..Water soluble ingredient has protocatechualdehyde and danshensu etc..In order to ensure that its whole active ingredient can be extracted
Out.The red sage root is extracted using first alcohol extracting, the method for rear water extraction.
The root of bidentate achyranthes：For amaranthaceous plant root of bidentate achyranthes Achyranthes bidentata B1 dry roots.With dispelling stasis of blood and stimulating the menstrual flow, tonifying liver
The pharmacology such as kidney, strengthening the bones and muscles, inducing diuresis for treating strangurtia, the effect ensuringd proper downward flow of the blood and regulation immunity, protection renal function, anti-inflammatory and antalgic, step-down is made
With.The root of bidentate achyranthes its chemical composition mainly has ginsenoside Ro (ginsenoside RO), panax japonicus saponin -1（PJS-1）, β-cast off a skin
Sterone（ecdysterone）, wall fern sterone B, shidasterone, oleanolic acid etc..Principle active component is plant sterone
Constituents, saponin component and alkaloids.Result of study shows that root of bidentate achyranthes optimum extraction process is the ethanol with 10 times of amounts 80%,
Extract 3 times, each 1h.Ketosteroid compouds is soluble in ethanol, and combines document above, and the root of bidentate achyranthes is intended extracting using ethanol.
Cassia seed：For the dry of legume Cassia Cassia obtusifolia L. or little Cassia tora Cassia tora L.
Dry mature seed.With The flat liver of heat-clearing, blood fat-reducing blood pressure-decreasing, relax bowel, improving eyesight fine effect of benefit.There are step-down, lipid-loweringing, antiplatelet
The effect of the modern pharmacologies such as cohesion.Arrange in pairs or groups with other Herb Teas, with the greasy effect of toxin expelling oil extraction.Cassia seed main component is Chrysophanol
(Chrysophanol), Physcion (Physcion), aurantio-obtusin (Aurantio-obtusin), 2,8-dihydroxy-1-methoxy-3-methylanthraquinone
Etc. (Obtusifolin) its main pharmacodynamics composition is polysaccharide, Anthraquinones and flavone compound.In order to carry to greatest extent
Depend on the active ingredient of pine torch, intend selecting ethanol to be extracted for solvent.
The root bark of Chinese wolf-berry：For matrimony vine of solanaceae plant Lycium chinense Mill. or lycium barbarum Lyciumbarbarum L.
Dry root skin.There is cool blood except steaming, clearing lung-heat fall fire.Its clinical practice extensively, can be used to treat functional low grade fever, sugar
The illnesss such as urine disease, toothache, hypertension, sore, chronic urticaria, surgical postoperative persistent fever.Compound in the root bark of Chinese wolf-berry is main
There are organic acid and its ester type compound, alkaloid compound, anthraquinone analog compound, brass class compound and lignanoids chemical combination
Thing.Studies have reported that, the main pharmacodynamics composition of the root bark of Chinese wolf-berry is contained abundant flavone compound, Main Flavonoids class compound
There is apiolin（Apigenin）, linarin（Linarin）, rheum emodin (Emodin), Physcion（Physcion）Deng.Celery
Element（Apigenin）With antitumor, anti-inflammatory, to various actives such as cardiovascular system, antianxieties.In order to extract to greatest extent
General flavone composition in the root bark of Chinese wolf-berry, selects ethanol to be extracted as solvent.
The bark of eucommia：For the dry bark of Eucommiaceae plant bark of eucommia Eucommia ulmoides Oliv..With strengthening by means of tonics,
The effect of muscle is antiabortive by force.There is the bark of eucommia enhancing immunologic function, lowering blood pressure and blood fat to suppress cholesterol rising, anti-oxidant etc. various
Pharmacological action.Containing chemical compositions such as lignanoids, iridoids, flavonoids, triterpenes, polysaccharide, gutta-percha in the bark of eucommia.
Wherein the most compound of content is lignanoids, iridoids, flavone compound.Lignanoids mainly has rosin spirit two
Glucoside（pinoresinol diglucoside）This main antihypertensive compositions, cloves lipidol diglucoside, olive fat
Element, catechin etc..Iridoids mainly has ulmoprenol（encommiol）, eucommioside（encommioside）, Geniposide
（genipin）, aucubin（aucubin）, ajugoside（ajugoside）, thunder flutter appropriate glycosides（reptoside）Deng.The bark of eucommia
Principle active component be Lignanoids compounds and iridoid.In order to extract to greatest extent its chlorogenic acid into
Point, the bark of eucommia is intended adopting water boiling and extraction.
Parasitic loranthus：For the dry zone leaf of Loranthaceae plant parasitic loranthus Taxillus chinensis (DC.) Danser
Stem branch.Property is bitter, sweet, flat, returns liver and kidney channel.There are wines used as antirheumatic, filling liver kidney, strengthening the bones and muscles, antiabortive unit, clinic cures mainly rheumatism numbness
Bitterly, the illness such as soreness and weakness of waist and knees, the powerless, fetal irritability of muscles and bones.Research shows, the difference of host to the pharmacological action of parasitic loranthus, change
Studying point principle active component that can produce impact parasitic loranthus includes little point of flavonoids, alkaloid, terpene and organic acid etc.
Sub- compound.In recent years chemical constitution study to parasitic loranthus is it has been shown that it is rich in flavone compound such as Quercetin, quercitin.
Documents and materials being combined from active ingredient contained by parasitic loranthus, using water extraction more parasitic loranthus, parasitic loranthus is intended being extracted using water.
Compared with prior art, it is an advantage of the current invention that：The present invention is different for the various metabolism of metabolic hypertension
Often design, it is intended to while stabilizing blood pressure, reach the function of adjusting blood pressure and blood lipoid metabolism, while adjusting metabolism is conducive to blood again
The control of pressure, treats both principal and secondary aspect of disease, significant for the preventing and treating of metabolic high blood pressure.
Specific embodiment
Below in conjunction with concrete preferred embodiment, the invention will be further described, but not thereby limiting the invention
Protection domain.
Embodiment one：
Active compound prepares：Red sage root 5g, root of bidentate achyranthes 10g, root bark of Chinese wolf-berry 10g, bark of eucommia 10g, cassia seed 5g, parasitic loranthus are measured by prescription
10g, green-tea extract 2g；
Preparation method embodiment one
Based on raw material described in embodiment one, preparation method embodiment one is comprised the following steps：
（1）Alcohol extracting：Above-mentioned red sage root 5g, cassia seed 5g, root bark of Chinese wolf-berry 10g and root of bidentate achyranthes 10g are mixed, mixture A is obtained, is used 60%
Twice, the addition of ethanol solution is respectively 8 times and 6 times of mixture A gross masses to ethanol solution refluxing extraction twice in front and back, front
Reflux extracting time twice is respectively 1h and 0.5h afterwards；Last alcohol extract is by being concentrated in vacuo to without alcohol taste, concentrated in vacuo
Temperature be 50 DEG C, vacuum is -0.1Mpa, and alcohol extracting concentrate is standby；
（2）Water extraction：To step（1）Add bark of eucommia 10g and parasitic loranthus 10g in the dregs of a decoction after middle alcohol extracting, obtain mixture B, it is right
Twice, the amount of water of water extraction twice is respectively 6 times and 4 times of mixture B gross masses in front and back, is carrying out first for mixture B water extractions
Mixture B is soaked into 0.5h in advance before secondary water extraction, in front and back the time of water extraction twice respectively 1.5h and 1h；Gained Aqueous extracts pass through
Being concentrated in vacuo to Aqueous extracts becomes thick medicinal extract, and temperature concentrated in vacuo is 60 DEG C, and vacuum is -0.1Mpa, gained thick medicinal extract
Density is 1.10；As water extracting liquid, standby；
（3）Powder processed：By step（1）The alcohol extracting concentrate for obtaining and step（2）After the water extracting liquid for obtaining merges mixing
It is vacuum dried, vacuum drying temperature is 50 DEG C, and vacuum is -0.1Mpa, and drying time, 12h obtained dry extract, by dry leaching
Cream is crushed, and crosses 60 mesh sieves, obtains extract powder, is added 2g green-tea extract powder, is well mixed, as capsule filling；
（4）Make finished product：By step（3）The capsule filling for obtaining loads capsule, and packaging obtains compound blood pressure reducing capsule
Finished product.
Embodiment two：
Active compound prepares：Red sage root 8g, root of bidentate achyranthes 12g, root bark of Chinese wolf-berry 12g, bark of eucommia 12g, cassia seed 8g, parasitic loranthus are measured by prescription
12g, green-tea extract 5g；
Preparation method embodiment two
Based on raw material described in embodiment two, preparation method embodiment two is comprised the following steps：
（1）Alcohol extracting：Above-mentioned red sage root 8g, cassia seed 8g, root bark of Chinese wolf-berry 12g and root of bidentate achyranthes 12g are mixed, mixture A is obtained, is used 70%
Twice, the addition of ethanol solution is respectively 10 times and 7 times of mixture A gross masses to ethanol solution refluxing extraction twice in front and back,
Reflux extracting time twice is respectively 1.5h and 1h in front and back；, by being concentrated in vacuo to without alcohol taste, vacuum is dense for last alcohol extract
The temperature of contracting is 60 DEG C, and vacuum is -0.1Mpa, and alcohol extracting concentrate is standby；
（2）Water extraction：To step（1）Add bark of eucommia 12g and parasitic loranthus 12g in the dregs of a decoction after middle alcohol extracting, obtain mixture B, it is right
Twice, the amount of water of water extraction twice is respectively 8 times and 5 times of mixture B gross masses in front and back, is carrying out first for mixture B water extractions
Mixture B is soaked into 1h in advance before secondary water extraction, in front and back the time of water extraction twice respectively 2h and 1.5h；Gained Aqueous extracts are by true
Sky is concentrated into Aqueous extracts becomes thick medicinal extract, and temperature concentrated in vacuo is 70 DEG C, and vacuum is -0.1Mpa, gained thick medicinal extract it is close
Spend for 1.12；As water extracting liquid, standby；
（3）Powder processed：By step（1）The alcohol extracting concentrate for obtaining and step（2）After the water extracting liquid for obtaining merges mixing
It is vacuum dried, vacuum drying temperature is 60 DEG C, and vacuum is -0.1Mpa, and drying time, 18h obtained dry extract, by dry leaching
Cream is crushed, and crosses 80 mesh sieves, obtains extract powder, is added 5g green-tea extract powder, is well mixed, as capsule filling；
（4）Make finished product：By step（3）The capsule filling for obtaining loads capsule, and packaging obtains compound blood pressure reducing capsule
Finished product.
Embodiment three：
Active compound prepares：Red sage root 10g, root of bidentate achyranthes 15g, root bark of Chinese wolf-berry 15g, bark of eucommia 15g, cassia seed 10g, parasitic loranthus are measured by prescription
15g, green-tea extract 5g；
Preparation method embodiment three
Based on raw material described in embodiment three, preparation method embodiment three is comprised the following steps：
（1）Alcohol extracting：Above-mentioned red sage root 10g, cassia seed 10g, root bark of Chinese wolf-berry 15g and root of bidentate achyranthes 15g are mixed, mixture A is obtained, is used
Twice, the addition of ethanol solution is respectively 12 times and 8 of mixture A gross masses to 80% ethanol solution refluxing extraction twice in front and back
Times, reflux extracting time twice is respectively 2h and 1h in front and back；, by being concentrated in vacuo to without alcohol taste, vacuum is dense for last alcohol extract
The temperature of contracting is 70 DEG C, and vacuum is -0.1Mpa, and alcohol extracting concentrate is standby；
（2）Water extraction：To step（1）Add bark of eucommia 15g and parasitic loranthus 15g in the dregs of a decoction after middle alcohol extracting, obtain mixture B, it is right
Twice, the amount of water of water extraction twice is respectively 9 times and 6 times of mixture B gross masses in front and back, is carrying out first for mixture B water extractions
Mixture B is soaked into 1h in advance before secondary water extraction, in front and back the time of water extraction twice respectively 2.5h and 2h；Gained Aqueous extracts are by true
Sky is concentrated into Aqueous extracts becomes thick medicinal extract, and temperature concentrated in vacuo is 80 DEG C, and vacuum is -0.1Mpa, gained thick medicinal extract it is close
Spend for 1.15；As water extracting liquid, standby；
（3）Powder processed：By step（1）The alcohol extracting concentrate for obtaining and step（2）After the water extracting liquid for obtaining merges mixing
It is vacuum dried, vacuum drying temperature is 70 DEG C, and vacuum is -0.1Mpa, and drying time, 24h obtained dry extract, by dry leaching
Cream is crushed, and crosses 100 mesh sieves, obtains extract powder, is added 5g green-tea extract powder, is well mixed, as capsule filling；
（4）Make finished product：By step（3）The capsule filling for obtaining loads capsule, and packaging obtains compound blood pressure reducing capsule
Finished product.
The experimental verification of the present invention
The present invention is in spontaneous hypertensive rat（SHR）Model, gives low dose of chain urea after 4 weeks Jing high glucose and high fat diet
Assistant rhzomorph (35 mg/kg) lumbar injection inducible metabolism hypertensive rat model.Compound blood pressure reducing capsule for treating is given, medicine is observed
Impact of the thing to rat blood pressure, blood fat, blood sugar, renal function and vascular remodeling.
Test method：Using the spontaneous hypertensive rat 50 of 12 week old, control group, model group, Kato are randomly divided into
Puli treatment group and Chinese medicine compound prescription blood pressure decreasing capsule low dosage, middle dosage, high-dose therapy group, are continuously treated by gastric infusion
8 weeks.Rat systolic pressure, diastolic pressure, the change of mean arterial pressure were detected per 3 days；Before administration and after administration, the total courage of blood drawing detection is solid
Alcohol, triglycerides, LDL-C（LDL-C）, HDL-C（HDL-C）, creatinine, urea nitrogen etc.
Index；After administration terminates, take aorta pectoralis, superior mesenteric artery routine formaldehyde and fix, FFPE carries out histopathology inspection
Look into.
Dosage
Captopril Treatment group：Captopril 100mg/kg every time, is administered 2 times daily；
Low dose therapy group：Compound blood pressure reducing capsule or compound blood pressure reducing glue made by the preparation method as described in embodiment one
Capsule, presses 50mg/kg every time to animal administration, is administered 2 times daily as low dose group；
Middle dosage treatment group：Compound blood pressure reducing glue made by preparation method described in the compound blood pressure reducing capsule as described in embodiment two
Capsule, presses 100mg/kg every time to animal administration, is administered 2 times daily as middle dose group；
High-dose therapy group：Compound blood pressure reducing glue made by preparation method described in the compound blood pressure reducing capsule as described in embodiment three
Capsule, presses 200mg/kg every time to animal administration, is administered 2 times daily as high dose group.
As a result：
1st, the impact to blood pressure.Before treatment, each group rat blood pressure is without significant difference.After treating 8 weeks, captopril contrast
Group, compound blood pressure reducing capsule low dose therapy group, middle dosage treatment group and compound blood pressure reducing capsule in high dose group substantially can be reduced generation
Thanking property Hypertensive Rats systolic pressure, diastolic pressure.As a result compound blood pressure reducing capsule is pointed out to reduce metabolic hypertensive rat blood pressure.
1. drug therapy of table SHR rat blood pressure levels after 8 weeks
All numerical value are represented with mean ± standard deviation.* P<0.05 vs metabolic hypertension model groups
2nd, the impact to blood fat.Before treatment, model group rats serum total cholesterol（TC）, triglycerides（TG）, low-density
Lipoprotein cholesterol（LDL-C）Higher than SHR control groups.HDL-C（HDL-C）Significantly lower than SHR control groups.
After treating 8 weeks, Captopril Treatment group is to rat T-CHOL（TC）, triglycerides（TG）, LDL-C
（LDL-C）And HDL-C（HDL-C）Without obvious effect, compound blood pressure reducing capsule low dose therapy group and compound
Blood pressure decreasing capsule high dose group can significantly reduce metabolic Hypertensive Rats T-CHOL, triglycerides, low-density lipoprotein courage
Sterol（LDL-C）And increasing high density lipoprotein cholesterol（HDL-C）.As a result compound blood pressure reducing capsule is pointed out to reduce metabolic high
Blood pressure rats blood lipid level.
2. drug therapy of table SHR rat fats after 8 weeks（mM）
All numerical value are represented with mean ± standard deviation.* P<0.05 vs SHR control groups.# P<0.05 vs metabolics are high
Blood pressure model group.
3rd, the impact to blood sugar.Before treatment, model group rats fasting blood-glucose is significantly higher than SHR control groups.After treating 8 weeks,
Captopril Treatment group is to rat fasting blood-glucose without obvious effect, compound blood pressure reducing capsule low dose therapy group, middle dosage treatment group
And compound blood pressure reducing capsule in high dose group can significantly reduce metabolic Hypertensive Rats fasting blood glucose level.As a result point out compound drop
Moulding capsule can reduce metabolic Hypertensive Rats blood sugar level.
3. drug therapy of table SHR rat fasting blood-glucoses before and after 8 weeks（mM）
All numerical value are represented with mean ± standard deviation.* P<0.05 vs SHR control groups.# P<0.05 vs metabolics are high
Blood pressure model group.
4th, the impact to renal function.Before treatment, model group rats serum creatinine, urea nitrogen levels are significantly higher than SHR control groups.
After treating 8 weeks, Captopril Treatment group is to rat serum creatinine, urea nitrogen without obvious effect, compound blood pressure reducing capsule low dose therapy
Group, middle dosage treatment group and compound blood pressure reducing capsule in high dose group can significantly reduce metabolic Hypertensive Rats serum creatinine, urea
Nitrogen level.As a result compound blood pressure reducing capsule is pointed out to have protective effect to metabolic Hypertensive Rats renal function.
4. drug therapy of table is to SHR rat serum creatinines, the impact of urea nitrogen
All numerical value are represented with mean ± standard deviation.* P<0.05 vs SHR control groups.# P<0.05 vs metabolics are high
Blood pressure model group.
5th, to aorta pectoralis and the impact of superior mesenteric artery reconstruct.Compared with SHR control groups, metabolic hypertension model
Group rat chest aorta, film smooth muscle cell proliferation and vascular wall is significantly thickened in superior mesenteric artery.Captopril Treatment group
Without significant change, the treatment of compound blood pressure reducing capsule low dose therapy group, middle dosage treatment group and compound blood pressure reducing capsule in high dose is notable
Suppress metabolic Hypertensive Rats aorta pectoralis, superior mesenteric artery medial thickening, mitigate morphological change.As a result point out compound
Blood pressure decreasing capsule has protective effect to metabolic Hypertensive Rats vascular remodeling.
Conclusion：The compound blood pressure reducing capsule energy effective control metabolic hypertensive rat blood pressure that the present invention is prepared, reduces blood
Fat, blood sugar, protect renal function, improve vascular remodeling.
Claims (8)
1. a kind of compound blood pressure reducing capsule for treating metabolic high blood pressure, it is characterised in that the filling of the compound blood pressure reducing capsule
If owner by made by Traditional Chinese drug mixture A alcohol extracting concentrate and water extracting liquid ECDC made by Traditional Chinese drug mixture B simultaneously,
The extract powder composition obtained after dry, crushing；The Traditional Chinese drug mixture A includes：5 ~ 10 mass parts of the red sage root, the root of bidentate achyranthes 10 ~
15 mass parts, 5 ~ 10 mass parts of 10 ~ 30 mass parts of the root bark of Chinese wolf-berry and cassia seed；The Traditional Chinese drug mixture B includes：The bark of eucommia
10 ~ 15 mass parts, 10 ~ 15 mass parts of parasitic loranthus and Traditional Chinese drug mixture A prepare the dregs of a decoction of alcohol extract generation；The compound
The filler of blood pressure decreasing capsule is (2 ~ 5) also including the mass ratio of green-tea extract, the extract powder and green-tea extract:1；It is described
Alcohol extracting concentrate is prepared via a method which to obtain：By the red sage root, cassia seed, the root bark of Chinese wolf-berry and the root of bidentate achyranthes according to the mass fraction
Proportioning is weighed and is mixed, and is obtained mixture A, is obtained alcohol extract at least twice with ethanol solution refluxing extraction, by decompression or vacuum
It is concentrated into without alcohol taste, obtains the alcohol extracting concentrate；The water extracting liquid is prepared via a method which to obtain：To alcohol extracting
Add the bark of eucommia and parasitic loranthus of the mass parts in the dregs of a decoction afterwards, obtain mixture B, mixture B water extractions are obtained at least twice
Aqueous extracts, by the Aqueous extracts are by decompression or are concentrated in vacuo to thick medicinal extract, obtain the water extracting liquid.
2. a kind of preparation method of the compound blood pressure reducing capsule for treating metabolic high blood pressure, it is characterised in that following from including
The raw material constituent of mass fraction proportioning：
1 ~ 5 part of green-tea extract
5 ~ 10 parts of the red sage root
10 ~ 15 parts of the root of bidentate achyranthes
10 ~ 30 parts of the root bark of Chinese wolf-berry
10 ~ 15 parts of the bark of eucommia
5 ~ 10 parts of cassia seed
10 ~ 15 parts of parasitic loranthus
Based on above-mentioned raw materials, the preparation method is comprised the following steps：
（1）Alcohol extracting：The above-mentioned red sage root, cassia seed, the root bark of Chinese wolf-berry and the root of bidentate achyranthes are weighed according to above-mentioned mass fraction proportioning and mixed, is obtained
Mixture A, with ethanol solution refluxing extraction at least twice, last alcohol extract is obtained by reducing pressure or being concentrated in vacuo to without alcohol taste
Alcohol extracting concentrate, it is standby；
（2）Water extraction：To step（1）Add the bark of eucommia and parasitic loranthus of above-mentioned mass parts in the dregs of a decoction after middle alcohol extracting, obtain mixture
B, to mixture B water extractions at least twice, last Aqueous extracts obtain water extraction concentration by reducing pressure or being concentrated in vacuo to thick medicinal extract
Liquid, it is standby；
（3）Powder processed：By step（1）The alcohol extracting concentrate for obtaining and step（2）The water extracting liquid for obtaining is carried out after merging mixing
Vacuum drying, obtain dry extract, dry extract crushed, cross 20 ~ 100 mesh sieves, obtain extract powder, by extract powder weight add 5 ~
30% green-tea extract powder, is well mixed, as capsule filling；
（4）Make finished product：By step（3）The capsule filling that obtains loads capsule, packaging, that is, obtain compound blood pressure reducing capsule into
Product.
3. the preparation method according to claim 2, it is characterised in that in step（1）In, with alcohol reflux extract time
For twice, the addition of ethanol solution is respectively 5 ~ 15 times and 3 ~ 10 times of mixture A gross masses to number twice in front and back, front
Reflux extracting time twice is respectively 0.5 ~ 2h and 0.5 ~ 1h afterwards, and the concentration of the ethanol solution is 50 ~ 90%.
4. the preparation method according to claim 2, it is characterised in that in step（1）In, temperature concentrated in vacuo is
50 ~ 70 DEG C, vacuum is -0.1Mpa.
5. the preparation method according to claim 2, it is characterised in that in step（2）In, the water extraction to mixture B
Number of times is for twice, the amount of water of water extraction twice is respectively 5 ~ 10 times and 3 ~ 8 times of mixture B gross masses in front and back, is entering
By the advance 0.5 ~ 1h of immersion of mixture B before row first time water extraction, in front and back the time of water extraction twice be respectively 0.5 ~ 3h and
0.5~2h。
6. the preparation method according to claim 2, it is characterised in that in step（2）In, temperature concentrated in vacuo is 60
~ 80 DEG C, vacuum is -0.1Mpa, and the density of gained thick medicinal extract is 1.10 ~ 1.15.
7. the preparation method according to claim 2, it is characterised in that in step（3）In, vacuum drying temperature is
50 ~ 70 DEG C, vacuum is -0.1Mpa, 12 ~ 24h of drying time.
8. the compound blood pressure reducing glue that one is as claimed in claim 1 or preparation method any one of claim 2 ~ 7 is obtained
Application of the capsule in treatment metabolic hypertension disease medicament is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410083094.3A CN103933216B (en) | 2014-03-10 | 2014-03-10 | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410083094.3A CN103933216B (en) | 2014-03-10 | 2014-03-10 | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103933216A CN103933216A (en) | 2014-07-23 |
| CN103933216B true CN103933216B (en) | 2017-04-05 |
Family
ID=51181273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410083094.3A Expired - Fee Related CN103933216B (en) | 2014-03-10 | 2014-03-10 | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933216B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10610555B2 (en) | 2015-12-09 | 2020-04-07 | Hlscience Co., Ltd. | Method for alleviating osteoarthritis by using composite (HL-Joint 100) of achyranthes bidentata, eucommin ulmoides oliver and pomegranate extracts, which has antiinflammatory effect caused by COX2 and PGE2 inhibition, cartilage protective effect caused by MMP-2 and -9 inhibition and cartilage regeneration effect caused by increase in type II collagen synthesis |
| CN112438965A (en) * | 2019-08-28 | 2021-03-05 | 青海省监狱管理局中心医院（青海红十字医院） | Atomizing agent for treating chronic obstructive pulmonary disease and preparation and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423421A (en) * | 2011-12-06 | 2012-04-25 | 陈中元 | Medicine for treating hypertension |
-
2014
- 2014-03-10 CN CN201410083094.3A patent/CN103933216B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423421A (en) * | 2011-12-06 | 2012-04-25 | 陈中元 | Medicine for treating hypertension |
Non-Patent Citations (2)
| Title |
|---|
| 仝小林教授辨治代谢性高血压经验总结;肖明良;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20131015;第E056-91页 * |
| 陆家龙老师治疗高血压病的临床经验总结;戴晓艳等;《云南中医中药杂志》;20011231;第22卷(第6期);第4-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103933216A (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1829519B1 (en) | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof | |
| CN101822832B (en) | Composition with anti-tumor effect and application thereof in preparing medicament for treating tumor | |
| CN1931261B (en) | Blood pressure and blood lipid lowering capsule and its preparation process | |
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN104107349A (en) | Chinese herbal medicine for three-hypers patients, and its administration method | |
| Zheng et al. | Research advances in lotus leaf as Chinese dietary herbal medicine | |
| CN104524146A (en) | Traditional Chinese medicine composition for prevention and adjuvant treatment of hypertensive, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition | |
| CN102302673B (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
| CN103933216B (en) | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN102380013A (en) | Medicinal composition for treating threatened abortion and habitual abortion and preparation method thereof | |
| CN105012853A (en) | Traditional Chinese medicine composition for treating hysteromyoma, preparation method and uses thereof | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN105288096B (en) | Medicine for treating whelk | |
| CN104491339A (en) | Seabuckthorn leaf composition for preventing and treating hyperlipidaemia and resisting thrombus and preparation method thereof | |
| CN107569528A (en) | A kind of pharmaceutical composition for treating hepatitis, pharmaceutical preparation and application and preparation method | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN105381267A (en) | Traditional Chinese medicine composition for treating hypertension and oral preparation and preparation method thereof | |
| CN101337057A (en) | Zhiqing granule and preparation method thereof | |
| CN105395842A (en) | Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof | |
| CN102309620B (en) | Chinese medicinal preparation for treating constipation and preparation method thereof | |
| CN104225550B (en) | The preparation method of blood-activating analgesic plaster | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN103611051A (en) | Traditional Chinese medicinal preparation for preventing and treating coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170405 Termination date: 20180310 |